

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine in Europe and Latin America (HERALD): a randomised, open-label, phase 2b/3 trial

Lancet Infectious Diseases, The
22, 329-340

DOI: [10.1016/s1473-3099\(21\)00677-0](https://doi.org/10.1016/s1473-3099(21)00677-0)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Principles for designing an optimal mRNA lipid nanoparticle vaccine. <i>Current Opinion in Biotechnology</i> , 2022, 73, 329-336.	6.6	102
3	Global emergence of SARS-CoV-2 variants: new foresight needed for improved vaccine efficacy. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 298-299.	9.1	8
4	Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. <i>Nature</i> , 2022, 601, 410-414.	27.8	71
5	Covid-19 vaccines and variants of concern: A review. <i>Reviews in Medical Virology</i> , 2022, 32, e2313.	8.3	201
6	mRNA Vaccines in the COVID-19 Pandemic and Beyond. <i>Annual Review of Medicine</i> , 2022, 73, 17-39.	12.2	120
7	Advanced Materials for SARS-CoV-2 Vaccines. <i>Advanced Materials</i> , 2022, 34, e2107781.	21.0	25
8	The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA. <i>Pharmaceutics</i> , 2022, 14, 460.	4.5	11
9	Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics. <i>Pharmaceutics</i> , 2022, 14, 398.	4.5	31
10	Adverse Events Reporting Quality of Randomized Controlled Trials of COVID-19 Vaccine Using the CONSORT Criteria for Reporting Harms: A Systematic Review. <i>Vaccines</i> , 2022, 10, 313.	4.4	5
11	COVID-19 mRNA vaccines: Platforms and current developments. <i>Molecular Therapy</i> , 2022, 30, 1850-1868.	8.2	102
12	Where Have the Dead Gone?. <i>Frontiers in Medicine</i> , 2022, 9, 837287.	2.6	0
13	A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant. <i>Vaccines</i> , 2022, 10, 508.	4.4	5
14	Current Advances in RNA Therapeutics for Human Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2736.	4.1	78
15	Epitranscriptomics of SARS-CoV-2 Infection. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 849298.	3.7	11
16	The Development of mRNA Vaccines for Infectious Diseases: Recent Updates. <i>Infection and Drug Resistance</i> , 2021, Volume 14, 5271-5285.	2.7	16
17	Scope of SARS-CoV-2 variants, mutations, and vaccine technologies. <i>The Egyptian Journal of Internal Medicine</i> , 2022, 34, 34.	0.9	5
18	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	62
19	Advances in COVID-19 mRNA vaccine development. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 94.	17.1	177

#	ARTICLE	IF	CITATIONS
20	Universal Flu mRNA Vaccine: Promises, Prospects, and Problems. <i>Vaccines</i> , 2022, 10, 709.	4.4	7
21	Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects. <i>Frontiers in Immunology</i> , 2022, 13, 843928.	4.8	25
22	The Current Landscape of mRNA Vaccines Against Viruses and Cancer—A Mini Review. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	12
23	Efficacy and Safety of the RBD-Dimer—Based Covid-19 Vaccine ZF2001 in Adults. <i>New England Journal of Medicine</i> , 2022, 386, 2097-2111.	27.0	147
25	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022, 20, .	5.5	149
26	Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects. <i>Current Opinion in Immunology</i> , 2022, 77, 102214.	5.5	7
27	Immune Response to SARS-CoV-2 Vaccine among Heart Transplant Recipients: A Systematic Review. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2022, 16, 117954842211053.	0.9	3
28	Lessons from SARS—CoV—2 and its variants (Review). <i>Molecular Medicine Reports</i> , 2022, 26, .	2.4	5
29	mRNA delivery technologies: Toward clinical translation. <i>International Review of Cell and Molecular Biology</i> , 2022, , 207-293.	3.2	5
30	Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	7
31	Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021. <i>International Immunology</i> , 2022, 34, 595-607.	4.0	19
32	Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> , 2022, 21, 1301-1318.	4.4	12
33	Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study. <i>Vaccine: X</i> , 2022, 11, 100189.	2.1	7
34	Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study. <i>EClinicalMedicine</i> , 2022, 51, 101542.	7.1	5
35	Extracellular Vesicle Mimetics: Preparation from Top—Down Approaches and Biological Functions. <i>Advanced Healthcare Materials</i> , 2022, 11, .	7.6	6
36	Safety and immunogenicity of a simian-adenovirus-vectored rabies vaccine: an open-label, non-randomised, dose-escalation, first-in-human, single-centre, phase 1 clinical trial. <i>Lancet Microbe, The</i> , 2022, 3, e663-e671.	7.3	12
37	A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	13
38	Efficacy and safety of COVID—19 vaccines: A network meta—analysis. <i>Journal of Evidence-Based Medicine</i> , 2022, 15, 245-262.	1.8	14

#	ARTICLE	IF	CITATIONS
39	Emerging trends of research on mRNA vaccines: A co-citation analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	3.3	1
40	Efficacy of Approved Versus Unapproved Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Randomized Blinded Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.9	2
41	Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	15
42	Assessing the Robustness of SARS-CoV-2 Vaccine Efficacy Trials: Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
43	SARS-COV-2 and Other mRNA Vaccines. <i>RNA Technologies</i> , 2022, , 113-138.	0.3	0
44	Viral vector and nucleic acid vaccines against COVID-19: A narrative review. <i>Frontiers in Microbiology</i> , 0, 13, .	3.5	14
45	Evidence of the Efficacy and the Effectiveness of First Generation COVID-19 Vaccines in Clinical Trials and Real-world Studies. <i>Zoonoses</i> , 2022, 2, .	1.1	0
47	Phenylalanine hydroxylase mRNA rescues the phenylketonuria phenotype in mice. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	4.1	9
48	A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 27, 309-323.	4.1	14
49	Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of <i>in vivo</i> imaging. <i>Theranostics</i> , 2022, 12, 7509-7531.	10.0	43
50	Identifying early adopters of COVID-19 vaccines in Latin America. <i>Vaccine</i> , 2022, , .	3.8	0
51	Adenovirus vector and mRNA vaccines: Mechanisms regulating their immunogenicity. <i>European Journal of Immunology</i> , 2023, 53, .	2.9	5
52	SARS-CoV-2 mRNA-based vaccines in the Aicardi GoutiÃres Syndrome. <i>Molecular Genetics and Metabolism</i> , 2022, 137, 320-327.	1.1	0
53	Innate sensing of mRNA vaccines. <i>Current Opinion in Immunology</i> , 2022, 79, 102249.	5.5	4
54	Efficacy of COVID-19 vaccines: a systematic review and network meta-analysis of phase 3 randomized controlled trials. <i>Pharmacological Reports</i> , 2022, 74, 1228-1237.	3.3	6
55	Innate immune mechanisms of mRNA vaccines. <i>Immunity</i> , 2022, 55, 1993-2005.	14.3	81
56	The landscape of mRNA nanomedicine. <i>Nature Medicine</i> , 2022, 28, 2273-2287.	30.7	152
57	The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case. <i>Journal of Pharmaceutical Sciences</i> , 2023, 112, 386-403.	3.3	40

#	ARTICLE	IF	CITATIONS
58	A review of COVID vaccines: success against a moving target. <i>British Medical Bulletin</i> , 2022, 144, 12-44.	6.9	5
59	Inhibition of c-Rel expression in myeloid and lymphoid cells with distearoyl -phosphatidylserine (DSPS) liposomal nanoparticles encapsulating therapeutic siRNA. <i>PLoS ONE</i> , 2022, 17, e0276905.	2.5	0
60	Current progress in the development of prophylactic and therapeutic vaccines. <i>Science China Life Sciences</i> , 2023, 66, 679-710.	4.9	13
61	Efficacy and safety of COVID-19 vaccines. <i>The Cochrane Library</i> , 2023, 2023, .	2.8	60
62	Recent developments in the immunopathology of COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 369-388.	5.7	33
63	Non-coding RNAs in human health and disease: potential function as biomarkers and therapeutic targets. <i>Functional and Integrative Genomics</i> , 2023, 23, .	3.5	39
64	Trial settles debate over best design for mRNA in COVID vaccines. <i>Nature</i> , 2023, 613, 419-420.	27.8	2
65	A single vaccination of nucleoside-modified Rabies mRNA vaccine induces prolonged highly protective immune responses in mice. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	4
66	A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2. <i>Nano Today</i> , 2023, 48, 101730.	11.9	10
67	Progress in vaccine development for infectious diseases—a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2023, 1524, 65-86.	3.8	3
68	Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet Microbe</i> , The, 2023, 4, e236-e246.	7.3	46
69	Development and applications of mRNA treatment based on lipid nanoparticles. <i>Biotechnology Advances</i> , 2023, 65, 108130.	11.7	10
70	mRNA vaccines: The future of prevention of viral infections?. <i>Journal of Medical Virology</i> , 2023, 95, .	5.0	24
71	mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!. <i>Vaccines</i> , 2023, 11, 507.	4.4	11
72	COVID-19 Vaccination Safety Profiles in Patients With Solid Tumour Cancers: A Systematic Review. <i>Clinical Oncology</i> , 2023, , .	1.4	2
73	Non-Viral Carriers for Nucleic Acids Delivery: Fundamentals and Current Applications. <i>Life</i> , 2023, 13, 903.	2.4	6
74	Pre-clinical models to define correlates of protection for SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	3
75	Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines. <i>Virology Journal</i> , 2023, 20, .	3.4	1

#	ARTICLE	IF	CITATIONS
76	Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial. EBioMedicine, 2023, 91, 104586.	6.1	6
77	mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV. Frontiers in Immunology, 0, 14, .	4.8	13
78	Randomized clinical trials of COVID-19 vaccines: Do adenovirus-vector vaccines have beneficial non-specific effects?. IScience, 2023, 26, 106733.	4.1	6
80	The Dawn of Microbiology. , 2023, , 17-26.		0
81	Assessing the robustness of COVID-19 vaccine efficacy trials: systematic review and meta-analysis, January 2023. Eurosurveillance, 2023, 28, .	7.0	1
82	Translatability scoring in prospective and retrospective COVID drug development cases. European Journal of Clinical Pharmacology, 0, , .	1.9	0
83	A mosquito AgTRIO mRNA vaccine contributes to immunity against malaria. Npj Vaccines, 2023, 8, .	6.0	2
84	Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SYS6006, as a fourth-dose booster following three doses of inactivated vaccines in healthy adults: an open-labeled Phase 1 trial. , 2023, 2, .		1
85	An update on vaccine status and the role of nanomedicine against SARSâ€CoVâ€2: A narrative review. Health Science Reports, 2023, 6, .	1.5	0
86	The role of vaccines in the COVID-19 pandemic: what have we learned?. Seminars in Immunopathology, 0, , .	6.1	13
87	Adjuvant physiochemistry and advanced nanotechnology for vaccine development. Chemical Society Reviews, 2023, 52, 5172-5254.	38.1	7
88	mRNA vaccines against respiratory viruses. Current Opinion in Infectious Diseases, 2023, 36, 385-393.	3.1	7
89	The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology. ACS Nano, 2023, 17, 15231-15253.	14.6	8
90	Future prospects in mRNA vaccine development. Biomedical Materials (Bristol), 2023, 18, 052006.	3.3	1
91	A Critical Assessment of COVID-19 Genomic Vaccines. Current Topics in Medicinal Chemistry, 2023, 23, .	2.1	0
92	RNA nanotechnology: A new chapter in targeted therapy. Colloids and Surfaces B: Biointerfaces, 2023, 230, 113533.	5.0	2
94	Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice. Molecular Therapy - Nucleic Acids, 2023, 34, 102045.	5.1	1
95	Engineered mRNA Delivery Systems for Biomedical Applications. Advanced Materials, 0, , .	21.0	0

#	ARTICLE	IF	CITATIONS
96	Pathogenesis of severe acute respiratory syndrome coronavirus-2 in nonhuman primates. <i>Current Opinion in Virology</i> , 2023, 63, 101375.	5.4	0
98	Covid-19 pandemic and scientific knowledge: logical implications for dealing with truth. <i>Ethics, Medicine and Public Health</i> , 2023, 31, 100947.	0.9	1
99	The advances of adjuvants in mRNA vaccines. <i>Npj Vaccines</i> , 2023, 8, .	6.0	3
100	Immunogenicity and Protective Efficacy of Nucleic Acid-Based Vaccines Against COVID-19: A Systematic Review. <i>Molecular Biotechnology</i> , 0, , .	2.4	0
101	Considerations on the Design of Lipid-based mRNA Vaccines Against Cancer. <i>Journal of Molecular Biology</i> , 2024, 436, 168385.	4.2	0
102	Effect of Platform Type on Clinical Efficacy of SARS-CoV-2 Vaccines in Prime Vaccination Settings: A Systematic Review and Meta-Regression of Randomized Controlled Trials. <i>Vaccines</i> , 2024, 12, 130.	4.4	0
103	Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis. <i>BMC Infectious Diseases</i> , 2024, 24, .	2.9	0